Crinetics Pharmaceuticals (CRNX) Tops Q4 EPS by 5c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($1.29), $0.05 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $4 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• argenx SE (ARGX) PT Raised to $1,115 at Leerink
• Popular stocks with increasing option volume: MU SPCX INTC AMD SNDK IREN PLTR AVGO SOFI NKE MSTR NBIS ORCL